Immunotherapy for the treatment of superficial and infiltrative bladder carcinoma.
作者信息
Cockett A T, Merguerian P A, di Sant'Agnese P A, Wheeless L L
机构信息
Department of Urology, University of Rochester, New York 14642.
出版信息
Prog Clin Biol Res. 1989;303:455-62.
PMID:2675003
Abstract
摘要
相似文献
1
Immunotherapy for the treatment of superficial and infiltrative bladder carcinoma.用于治疗浅表性和浸润性膀胱癌的免疫疗法。
Prog Clin Biol Res. 1989;303:455-62.
2
Predicting bacillus Calmette-Guerin immunotherapy effectiveness.预测卡介苗免疫疗法的有效性。
J Urol. 2007 Dec;178(6):2247-8. doi: 10.1016/j.juro.2007.08.075. Epub 2007 Oct 22.
3
Management of superficial transitional cell carcinoma of the bladder.膀胱浅表性移行细胞癌的管理
Semin Urol. 1993 Nov;11(4):193-204.
4
Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.关于以下内容的编辑评论：在尿路上皮细胞癌模型中，塞来昔布作为单一药物以及与卡介苗免疫疗法联合使用时具有强大的抗肿瘤作用。
Eur Urol. 2008 Sep;54(3):629-30. doi: 10.1016/j.eururo.2008.01.014. Epub 2008 Jan 15.
5
[BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
Harefuah. 1999 Apr 15;136(8):628-33.
6
Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.卡介苗（BCG）免疫疗法治疗浅表性膀胱癌的并发症。
Compr Ther. 1994;20(12):695-701.
7
8
Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.卡介苗膀胱内灌注治疗T1期浅表性膀胱癌
Urol Int. 2008;80(1):74-9. doi: 10.1159/000111734. Epub 2008 Jan 18.
9
BCG in carcinoma in situ and superficial bladder tumors.
Prog Clin Biol Res. 1988;269:497-510.
10
[Our experience in the treatment of superficial cancer of the bladder with BCG].
Arch Esp Urol. 1989 May;42(4):325-7.
Zotero 插件